Commentary: Time to improve the reporting of harms in randomized controlled trials.

[1]  L. Hazell,et al.  Analysis and reporting of adverse events in randomised controlled trials: a review , 2019, BMJ Open.

[2]  J. Berlin,et al.  Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective , 2016, British Medical Journal.

[3]  Tony Tse,et al.  Trial Reporting in ClinicalTrials.gov - The Final Rule. , 2016, The New England journal of medicine.

[4]  D. Altman,et al.  Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews , 2014, BMJ : British Medical Journal.

[5]  Lisa Hartling,et al.  Quality of reporting in systematic reviews of adverse events: systematic review , 2014, BMJ : British Medical Journal.

[6]  E. Chen,et al.  Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Gamble,et al.  Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension , 2013, BMJ Open.

[8]  S. Ayis,et al.  Adverse event reporting in randomised controlled trials of neuropathic pain: Considerations for future practice , 2013, PAIN.

[9]  David Moher,et al.  Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane reviewa , 2012, Systematic Reviews.

[10]  Robert M Califf,et al.  Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. , 2012, JAMA.

[11]  David Moher,et al.  AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. , 2010, Journal of clinical epidemiology.

[12]  P. Dahm,et al.  Reporting of harm in randomized controlled trials published in the urological literature. , 2009, The Journal of urology.

[13]  P. Bossuyt,et al.  The quality of diagnostic accuracy studies since the STARD statement , 2006, Neurology.

[14]  D. Moher,et al.  Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review , 2006, The Medical journal of Australia.

[15]  J. Ioannidis,et al.  Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.

[16]  I. Mackie,et al.  Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial , 2001, The Lancet.

[17]  J. Ioannidis,et al.  Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. , 2001, JAMA.

[18]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.